Sunday, December 28, 2003

nvidia some health cases

 Jensen's biggest investment in life scxiences ai beyond nvidia may be recursion; within nvidia ai of biotech sometimes called Clara; in valey Daphne Koler lonmg recognised as stamford biotech ace also co-founder corsera/mooc; at berkeley jennifer doudna nmobel prize for Crispr gene databank; demih hasabis deep mind leader deepming alphafold3 generated 250 million protein databank (London/Cambbriege/Google Moutain View)

March 2024
, Chief Technology Officer, Recursion
As the pace of AI-enabled drug discovery accelerates, you’ll hear firsthand how companies like Recursion and NVIDIA are pushing the boundaries of research to deliver some of the most exciting and impactful solutions for humanity.
March 2024
, Group Lead, Life Sciences Developer Relations, NVIDIA
, Founder and Chief Executive Officer, Odyssey Therapeutics
, Founder and Chief Executive Officer, Adjunct Professor of Computer Science, Insitro, Stanford University
, Chief Scientific Officer, Relation Therapeutics 
, Co-Founder and Chief Technology Officer, VantAI
Exploring the intersection of biology and artificial intelligence, this panel will delve into the transformative role of AI, from graph machine learning to large language models, in drug discovery.

March 2022
, Clara Discovery PM, NVIDIA
, Healthcare and Life Science Product Marketing, NVIDIA
, Senior AI and Deep Learning Scientist, NVIDIA
, Principal Solutions Architect, NVIDIA
, Senior Alliance Manager, NVIDIA
Learn from data scientists, computational chemists, computational biologists, and other experts in the life sciences about how they are using in silico methods for virtual screening, molecular dynamics, simulations, 3D protein predictions, protein engineering, and more.


January 2023
, Ph.D., Executive Director in the Drug Discovery Group , Schrodinger
, Director, Global Head of Business Development, Healthcare & Life Sciences, NVIDIA
Learn how to leverage HPC and GPU technology to explore and accurately profile vast amounts of drug-like chemical space in-silico.
March 2023
, Medical Imaging Alliance Manager, NVIDIA
, Group Lead, Life Sciences Developer Relations, NVIDIA
, Clara Discovery Product Manager, NVIDIA
, Global Head of Genomics Alliances, NVIDIA
, Product Manager, NVIDIA
, Senior Scientist - Genomics, HPC and AI, NVIDIA
, Genomics Product Lead, NVIDIA
, Holoscan Product Management Lead, NVIDIA
, Senior Alliance Manager, NVIDIA
, Senior Manager for Healthcare AI Products, NVIDIA
, Director of Product for Healthcare AI, NVIDIA
, Global Marketing Manager, NVIDIA
, Senior Technical Product Manager - Medical Devices, NVIDIA
Healthcare and life sciences demand accelerated and optimized workflows for genomics, radiology, pathology, medical devices, and in silico drug discovery. With NVIDIA, data scientists, bioinformaticians, and developers can harness the power of artificial intelligence and high performance computing to provide better care for patients 

March 2024
, Research Engineer/Co-Founder, Sorbonne Université/Qubit-Pharmaceuticals
It's a long and costly process with a low success rate, but it can be drastically accelerated and the associated cost mitigated by ‘in silico’ molecular simulations, provided that these are accurate and fast enough.

March 2024
, Co-Founder & Chief Executive Officer, RECEPTOR.AI
We'll explain how the workflow brings together a spectrum of in-silico drug discovery methods: protein structure prediction, binding pocket identification, molecule generation, virtual screening, and ML-powered molecular docking.

, T-Mobile
, Hugging Face
, NVIDIA
, RingCentral
Conversational AI is opening new opportunities in every industry with applications like real-time transcription, virtual assistants, and chatbots. Hear from industry leaders about how deploying speech and language technologies enhanced their businesses, and challenges, tips, and emerging trends for conversational AI in 

No comments:

Post a Comment